Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Illegal cannabis use is common among Danes with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Natalizumab and fingolimod were approved for treatment of active relapsing-remitting multiple sclerosis (RRMS) in Denmark in 2006 and 2011, respectively. There have been no randomized head-to-head studies comparing the two drugs.

OBJECTIVE: To compare the clinical efficacy of natalizumab and fingolimod.

METHODS: Data on all Danish RRMS patients who started their first second-line treatment with natalizumab or fingolimod from July 2011 to March 2015 were prospectively recorded in the Danish Multiple Sclerosis (MS) Treatment Register. The two treatment arms were 1:1 propensity score matched by baseline covariates using 'nearest neighbour' method.

RESULTS: Propensity score matching left 928 of 1309 RRMS cases, 464 in each treatment group. The on-treatment annualized relapse rate was 0.296 (95% confidence interval (CI): 0.26-0.34) for natalizumab and 0.307 (95% CI: 0.27-0.35) for fingolimod. The adjusted relapse rate ratio was 0.93 (95% CI: 0.74-1.17; p = 0.53). Mean time to first relapse was 2.55 and 2.56 years, respectively ( p = 0.76). There was no difference in change of Expanded Disability Status Scale (EDSS).

CONCLUSION: We found no differences in clinical disease activity between natalizumab- and fingolimod-treated RRMS patients in this real-life observational study. However, the lack of magnetic resonance imaging (MRI) data for the propensity score matching may conceal a higher efficacy of natalizumab.

Original languageEnglish
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume23
Issue number2
Pages (from-to)234-241
Number of pages8
ISSN1352-4585
DOIs
Publication statusPublished - Feb 2017

    Research areas

  • Journal Article

ID: 52217196